Virginia health officials confirm state's second case of measles in teen
A second case of measles has been confirmed in Virginia.
State health officials say the patient is a teen between the ages of 13 and 17.
There are several potential exposure sites that you can see below.
RICHMOND, Va. - The Virginia Department of Health has confirmed the state's second case of measles.
They say the patient is a teenager between the ages of 13 and 17 in the Northwest region who recently traveled internationally.
What you need to know
Below are the dates, times, and locations of potential exposure sites in Virginia:
Charlottesville Albemarle Airport on Tuesday, May 20 between 2:15 p.m. and 5:30 p.m.
Play it Again Sports, located at 1885 Seminole Trail in Charlottesville on Tuesday, May 20 from 2:40 p.m. to 5 p.m.
Goodwill Store and Donation Center, located at 440 Gander Drive in Charlottesville on Tuesday, May 20 from 3:10 p.m. to 5:30 p.m.
UVA Health Primary Care Riverside, located at 2335 Seminole Lane, Suite 200 in Charlottesville on Thursday, May 22 from 2 p.m. to 7:10 p.m.
UVA Health University Medical Center Emergency Department, located at 1215 Lee St. in Charlottesville on Friday, May 23 from 12 a.m. to 6 a.m.
Dig deeper
The state's first case of measles was diagnosed in April. The infected patient was a child up to four years old who recently traveled internationally prior to testing positive.
The potential exposure site in that case was a Kaiser Permanente Caton Hill Medical Center Advanced Urgent Care in Northern Virginia. Health officials said the child had visited the center while contagious.
Why you should care
Measles is highly contagious all year round.
The Virginia Department of Health says anyone exposed is considered to "be at risk of developing measles and should contact their healthcare provider immediately."
The Virginia Department of Health goes on to say those exposed should watch for symptoms for three weeks after the date of the potential exposure.
Measles symptoms include fever, runny nose and watery eyes before a rash appears on the face and body. If symptoms of measles are noticed, the person exposed should immediately self-isolate by staying home.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
I'm a digital clutter coach, but my work hit close to home when my dad died. I was glad I'd taken these steps ahead of time.
I'm a digital clutter coach, but my work had never hit close to home until my dad passed away. When he did, I was glad that I'd taken steps ahead of time to be organized. Saving his logins, organizing a Dropbox, and keeping his phone active helped during a tough time. I never imagined that being organized in my digital life would help my family during one of our toughest times. My father had Parkinson's disease for many years. But in 2020, at the height of the pandemic, it got worse, fast. He was suddenly adding extra zeros to checks, looking for the TV remote in the coat closet, and he got lost driving to the grocery store four blocks away. (That was the last time he drove.) My way of coping with his sudden decline was to kick my organizational skills into overdrive. Though I'm a digital clutter coach by profession, it had never hit this close to home. Here's what I did that made an extremely difficult time easier for me and my family. I got a clear picture of his assets and organized his documents digitally I worked with him (as much as he was able) and my mom to gather all of the financial statements, wills, powers of attorney, insurance policies, health directives, medicines, and more. I saved these files in Dropbox so that they could be accessed from anywhere and easily shared with others. (Another great option is Trustworthy, which has certified experts who can help gather all of these documents into one user-friendly hub.) Taking it a step further, I shared those documents pre-emptively with his healthcare providers, banks, insurance companies, and more to ensure I could speak to them on his behalf. I used my phone as a scanner and a fax machine When my dad ultimately passed in November of 2020, we found ourselves signing slews of documents and faxing dozens of death certificates. My phone became a powerful tool that I could use on the go, whether I was at the funeral home, the bank, or my mom's house. I used my phone to scan documents directly into Dropbox, but one of the most surprising and helpful things was using it to fax. I learned quickly that many banks and insurance companies do things "old school." I sent faxes via a phone app called GeniusFax. It was super affordable and saved me the stress of running around town trying to track down a fax machine. (Hello, 1985.) I saved his logins, and I kept his phone active I stored all of my dad's usernames, passwords, and answers to security questions (like, who was your first grade teacher) in 1Password so that I could access accounts on his behalf. I created a tag called "Dad" so that I could easily find all items related to him amid my own passwords. We also somehow had the foresight not to deactivate his phone right away. That was crucial when we needed to receive 2-step verification texts when logging into his accounts. I used facial recognition to gather photos I was tasked with making the video for his memorial service, so I asked family and friends to use the facial recognition feature on their phones and add their favorite photos of Dad to a shared photo album. This made it so easy to create a beautiful tribute video, and to this day, my mom still watches it. I miss my dad's goofy, dry humor, our peaceful canoe rides together, and his gentle spirit every day. But as strange as it sounds, learning how to use this technology made it easier to stay present, process my grief, and honor my dad. It made an incredibly difficult time just a little more bearable. Read the original article on Business Insider Solve the daily Crossword
Associated Press
27 minutes ago
- Associated Press
OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
New York, New York--(Newsfile Corp. - August 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported second quarter 2025 financial results ended June 30, 2025 and provided a business update. 'The Company gained significant momentum in the second quarter as we began to make meaningful clinical and regulatory progress on our path towards bringing the first new treatment for osteosarcoma to market in the United States in the last 40 years,' said Paul Romness, MPH, Chairman & CEO of OS Therapies. 'Now midway through the third quarter, we have updated interim 2-year overall survival data readout that shows a statistically significant benefit for OST-HER2 treated patients, coupled with the final 12-month Event Free Survival ('EFS') that also shows statistically significant benefit for OST-HER2 treated patients, from our Phase 2b trial of OST-HER2 in the prevention or delay of recurrence in recurrent, fully resected, pulmonary metastatic osteosarcoma. The congruence between the overall survival and EFS data gives our clinical and regulatory teams confidence that we are on strong footing as we march towards our goal of receiving a Biologics Licensing Application ('BLA') by the U.S. Food and Drug Administration ('FDA') for OST-HER2 under the Accelerated Approval Program ('Accelerated Approval'). Importantly, our U.S. commercial partnership with Eversana positions us to be able to bring OST-HER2 to osteosarcoma patients in the first half of 2026.' Mr. Romness continued, 'So long as we receive a BLA for OST-HER2 prior to September 30, 2026, the Company is eligible to be granted a priority review voucher ('PRV'), as a result of OST-HER2's rare pediatric disease designation, that it intends to subsequently sell. Given that the most recent publicly disclosed PRV sale transaction was valued at $160 million in June 2025 versus a May 2025 PRV transaction that was valued at $155 million, we believe that the PRV market is likely to continue to see an increase in value moving forward.' 'Additionally, we have made progress internationally with our recent Innovative Licensing and Access Pathway ('ILAP') submission, which formally begins the regulatory process for OST-HER2 with the United Kingdom's Medicines and Healthcare products Regulatory Agency ('MHRA') following a successful Scientific Advice Meeting ('SAM'), during which we were advised that MHRA recommends a synchronization of the approval process with the FDA via Project Orbis within 30 days of the BLA submission. We have also scheduled an October 2025 rapporteur meeting with the European Medicines Agency ('EMA') as the starting point for the approval process with Europe,' noted Mr. Romness. Second Quarter 2025 Corporate Highlights: Third Quarter 2025 Progress to Date and Future Milestones Progress to Date: Upcoming 2025 Milestones: Loss from Operations: The Company recorded a net operating loss of $4.537 million in the second quarter of 2025, compared with a net operating loss of $1.557 million in the second quarter of 2024. The increase in net loss was largely due to expenses associated with U.S. and international regulatory activities related to the OST-HER2 Phase 2b osteosarcoma program. Net loss per share in the second quarter of 2025 was $0.19 on 25.114 million weighted average shares outstanding, compared to second quarter of 2024 where the Company delivered a net loss of $0.26 per share on 5.991 million weighted average shares outstanding. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as 'anticipate,' 'expect,' 'intend,' 'may,' 'will,' 'should' or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in 'Risk Factors' in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. OS Therapies Contact Information: Investor Relations Harrison Seidner, PhD WaterSeid Partners [email protected] Public Relations Stephanie Chen Elev8 New Media [email protected] To view the source version of this press release, please visit
Associated Press
27 minutes ago
- Associated Press
STELLUS CAPITAL MANAGEMENT, LLC PROVIDES UNITRANCHE FINANCING IN SUPPORT OF RALLYDAY PARTNERS' INVESTMENT IN ELDER CARE HOMECARE
HOUSTON, Aug. 19, 2025 /PRNewswire/ -- Stellus Capital Management, LLC ('Stellus') announced today that its affiliates provided senior debt financing and an equity co-investment in support of Rallyday Partners' ('Rallyday') investment in Elder Care Homecare ('Elder Care'), a premium senior home care agency serving New York, New Jersey, Connecticut, and Massachusetts. Established in 2008, Elder Care provides a suite of offerings, including personal care, companionship, skilled nursing, memory care, and rehabilitation, helping seniors thrive at home. Elder Care leverages highly trained caregivers, robust clinical oversight, and a personalized approach to deliver best-in-class solutions for every family it serves. Frank A. Corvino, Managing Partner at Rallyday, said, 'We are thrilled to partner with Elder Care, a team driven by deep empathy and operational excellence at every level. Their devotion to supporting seniors and their families distinguishes them as true leaders in the home care sector', adding 'We are grateful for the partnership with Stellus on this exciting opportunity and look forward to their continued support as Elder Care continues to grow its footprint. The Stellus team was thoughtful and efficient throughout the entire financing process.' John Sievers, Managing Director at Stellus, added, 'Elder Care has established a reputation as a premiere home care agency in the Northeast given its commitment to helping seniors and their families navigate the aging journey with the highest quality of care. We are excited to partner with Rallyday and the Elder Care management team on their ongoing success and believe Elder Care's best-in-class service offering is well positioned to meet increased demand from seniors and their preference to receive superior care in the comfort of their own home.' View original content to download multimedia: SOURCE Stellus Capital Management, LLC
